Shionogi & Co. Ltd., a manufacturer and marketer of pharmaceutical and diagnostics products, has signed an exclusive worldwide licensing agreement with OncoTherapy Science Inc. to develop, manufacture and market cancer peptide vaccines. With the completion of this new agreement, Shionogi is expanding its relationship with OTS to encompass worldwide rights to all peptide vaccines discovered by OTS, for all indications. As part of this agreement, OTS will receive an up-front payment, milestone payments at successful completion of key development phases, and royalties on sales.